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When looking ahead, it is really important to 
know where we have come from. This allows 
us to project identified trends and to reflect 
on the tremendous amount of change that 
can happen over a relatively short period. 
Reflect for a moment on the intensity of 
the debate regarding the use of intraocular 
lenses (IOLs) in low-income settings in the 
1990s. As they were still very expensive, 
some insisted that aphakic correction after 
surgery was the best approach for these 
countries. The subsequent availability of 
low-cost IOLs made the debate irrelevant. 
It dramatically changed our ability to provide 
modern IOL cataract surgery and control 
cataract blindness worldwide, and it laid the 
basis for VISION 2020. Other dramatic 
changes occurred with the introduction of 
ivermectin for onchocerciasis and azithro-
mycin for trachoma, which gave us the 
ability to eliminate these two devastating 
and previously intractable causes of 
blindness. Our medical management of 
glaucoma or of age-related macular degen-
eration today is totally different from what it 
was 20 years ago, although there is still a 
long way to go. Our approach to refractive 
error has also altered dramatically, thanks to 
the recognition of its importance and the 
availability of high-quality, low-cost spectacles.
So, given what we know about the past, 
what are the challenges we face in the future?
Doing what we know
The gap between knowledge and practice
To my mind, the single biggest challenge we 
face – and the one which will offer by far the 
biggest pay-off – is the challenge of fully 
applying what we already know. We know 
how to cure cataract blindness, how to cure 
uncorrected refractive error, how to 
eliminate trachoma and onchocerciasis, 
and how to prevent most blindness from 
diabetic retinopathy. We do not need to wait 
for a new gene to be discovered or a new 
laser. Why, then, aren’t we putting this 
knowledge into practice right now?
VISION 2020 recognises that three-quarters 
of all blindness worldwide is either avoidable 
or preventable with what we currently know 
and it aims to bridge the existing gap between 
knowledge and practice. The VISION 2020 
initiative emphasises disease control, but it 
also recognises the need for eye care to be 
delivered through national programmes that 
are tailored to individual countries. The initi-
ative also rightly emphasises human resource 
development and infrastructure. 
However, none of this is possible without 
money! Non-governmental organisations 
and donor agencies can provide some level 
of ongoing funding, as well as flexible 
start-up money for new initiatives. Yet 
long-term funding for ongoing blindness 
prevention and eye care must eventually 
come from governments or their insurance 
programmes, although individuals 
themselves will continue to pay some costs. 
The crucial importance of advocacy 
What is really needed, therefore, is strong 
advocacy programmes to alert governments 
to the importance of eye care, the costs of not 
doing more, and the benefits of intervening 
to prevent avoidable blindness.  
Evidence for advocacy. For effective 
advocacy, good data is essential. 
National, population-based prevalence  •	
data on blindness can be invaluable, but 
using data from similar countries, extrapo-
lated with national demographic data, is 
almost as effective and far more cost-
effective and timely. 
Exciting advances are being made in  •	
quantifying the ‘burden of disease’ or the 
‘loss of wellbeing’ attributable to vision 
loss and translating it into monetary terms 
(such as US dollar per quality-adjusted 
life-year or QALY). 
Eye care interventions are amongst the  •	
most cost-effective of all health care inter-
ventions, in terms of reducing the number 
of years people would otherwise have lived 
with a disability (this is quantified as 
disability-adjusted life-years or DALYs). 
Economic arguments such as these are  •	
what governments and finance departments 
understand. For example, one can show 
that for each US dollar spent on eye care, 
there is a US $5 return to the community. 
Such an objective financial argument 
carries more weight than an emotional call 
for action to stop people losing their sight. 
It is also important to monitor and  •	
evaluate our programmes to show their 
ongoing success, efficiency, and impact 
– and to add this to the case for eye care 
we are trying to build. 
Developing advocacy skills. With solid 
evidence being available to support the estab-
lishment of eye care programmes, the focus 
moves to the need for strong advocacy skills. 
Key members of eye teams should receive  •	
specific training to enable them to succinctly 
state and present the case for eye health. 
Some work has already started on this –  •	
workshops run by the International Agency 
for the Prevention of Blindness and the 
International Centre for Eye Health, as well 
as various activities by the International 
Council for Ophthalmology – but much 
more will be needed in the coming years. 
There are a growing number of good  •	
examples of successful case development 
and advocacy at a national level, but 
these successes will need to be repeated 
many times, for each country and of 
course at the international level through 
the World Health Assembly.
Recognising the changing 
demography
The population is getting older 
worldwide
Over the last 50 years, life expectancy has  •	
increased by about 20 years around the 
world, except in those countries most 
affected by HIV/AIDS. As a consequence, 
the world population is getting older, with 
the number of elderly people set to double 
in the next 20 years. 
Because the frequency of blindness and  •	
vision loss increases with age, the demand 
for eye services will increase exponentially 
as populations grow older – this will need 
to be taken into account when planning 
eye care services. For example, the 
cataract surgical rate a country will need 
to achieve in order to eliminate blindness 
may increase significantly if there are 
more older people with cataract.
 In addition, the indications for surgery  •	
may change over time, as countries grow 
and people need to be able to read or 
drive a car in order to remain economically 
active; this will further increase the need 
for cataract surgery. 
New patterns of disease
The changing demographic structure, 
coupled with economic growth, has also led 
to dramatic changes in the patterns of 
disease. Diseases particular to older people, 
especially age-related macular degener-
ation (AMD) and glaucoma, have become 
increasingly important. 
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Older woman with cataract. ViET nAMAMD and glaucoma
AMD is now the leading cause of  •	
blindness in most developed 
countries; it was not even listed as 
an important cause 50 or 100 
years ago! Glaucoma too will 
become increasingly important. 
However, for both AMD and  •	
glaucoma, prevention is tough, 
treatment long and expensive, and 
at present only partially effective.
In addition, interventions are very  •	
costly, but relatively inefficient, and 
both diseases require good low 
vision services to help people make 
the most of their remaining vision.
Diabetes
Vision loss from diabetes is another  •	
growing problem resulting from 
increased life expectancy and 
changing lifestyles. People who 
would ordinarily have died of old 
age now live long enough to 
experience the retinal complica-
tions of the disease (diabetic 
retinopathy). 
Whereas diabetes once only  •	
affected people in high-income 
countries, the number of people 
with type-2 diabetes and obesity 
in low- and middle-income 
countries is now rapidly growing. 
As ophthalmologists cannot  •	
screen every person with diabetes 
for diabetic retinopathy on an 
annual basis, there is a pressing need to 
develop effective screening strategies with 
teams working in primary care and 
diabetes clinics. These teams might 
include ophthalmic nurses, optometrists, 
or other suitably trained mid-level personnel. 
Changing interventions. These new 
patterns of disease will lead to changes in 
interventions. Ongoing, chronic conditions 
such as diabetic retinopathy, AMD, and 
glaucoma require a very different approach 
from the almost one-off contact required for 
cataract surgery. For example, persuading 
diabetes patients to change their behaviour 
may become an important way to prevent 
blindness from diabetic retinopathy.
Therapeutic advances
AMD treatment
In the field of AMD, I feel sure there will be 
very exciting and rapid advances, particularly 
concerning drugs that inhibit or reverse the 
growth of new vessels; both better compounds 
and better delivery methods are being 
developed – specifically, vascular endothelial 
growth factor (VEGF) blockers or inhibitors 
(see article on page 50). The challenge will 
be to make these drugs available at prices 
both affordable and justifiable on a cost-
effectiveness basis. The current drugs are 
often unaffordable by most (even in high-
income countries) and not cost-effective. 
The biggest pay-off will be for drugs that slow 
or prevent the progression of the disease.
Glaucoma treatment
In the case of glaucoma treatment, we are 
also likely to witness the further devel-
opment of drugs that are more convenient 
to administer and have fewer side effects. 
However, these new drugs will have to be far 
superior to justify prices that are higher than 
those of the present drugs. 
It would be much better if we were 
able to diagnose the people with glaucoma 
who are currently undiagnosed (estimated 
at 50% of all cases). It would also be 
better if we were able to provide laser 
trabeculoplasty as the first-line therapy, 
rather than drugs that are expensive, have 
more side effects, and are plagued by 
poor compliance. However, the real break-
through for glaucoma will be a safe and 
effective filtering procedure, such as a 
surgical drainage stent. Advances in our 
understanding of wound healing and 
nanofabrication should allow a simple-to-
insert stent to give simple surgical control 
of pressure.
Gene chips
The ready availability of gene chips in the 
future could enable improved diagnosis 
and specifically tailored treatments for 
various eye diseases, including AMD and 
glaucoma. Gene chips are already available 
as prototypes, but there is likely to be 
much development as more and more 
genes are identified for various conditions 
and differential responses to treatment 
are determined. 
Accommodating IOLs
All of ophthalmology and eye care 
would be revolutionised by the 
development of an effective and 
safe accommodating IOL. This 
would immediately replace all 
current IOLs and would further 
increase the demand for cataract 
surgery at earlier stages of vision 
loss. In addition, an accommo-
dating IOL would also replace 
most refractive surgery and 
therefore affect both the Excimer 
laser surgery and the contact 
lens markets. Moreover, 
accommodating IOLs could well 
become the preferred option 
for the correction of presbyopia
and make bifocal spectacles 
redundant. Wouldn’t that be a 
revolution!
Bionic eye and stem cell 
biology
Another exciting possibility – 
although likely to be out of the 
financial reach of most people – 
is the ‘bionic eye’ for those with 
severe outer retinal damage. 
Such implants are likely to be 
extremely expensive and will be far 
more challenging to develop than 
the successful bionic ear, which 
has been in use for 20 years and 
still costs over US $20,000. 
Stem cell biology also offers hope for 
those with conditions which are currently 
difficult to treat, such as some forms of 
corneal blindness. 
Childhood blindness
I hope it is only my ignorance, but I do 
not see any major breakthroughs in 
childhood blindness. Genetic identification 
may help to guide planned pregnancies in 
high-income countries and the first 
successful examples of gene transfer 
appear to offer exciting possibilities for 
treating inherited retinal degeneration. 
However, neither of these advances is 
likely to have a major impact in low- and 
middle-income countries in the foreseeable 
future. As far as I can see, the major 
advances will result from doing what we 
already know how to do, but doing it better: 
rubella and measles vaccination, clean 
faces, improving vitamin A intake, improving 
management of  amblyopia (as it is needed 
after cataract, glaucoma, and squint 
treatment), monitoring of oxygen levels, 
early detection and low vision training, etc.
Conclusion
I will probably be embarrassed by some of 
these predictions by the time this is 
published and, surely, many of them will 
turn out to be foolish with hindsight. 
However, even if only one or two turn out to 
be correct, we will have a very exciting time 
over the next 20 years.
As the frequency of blindness and vision loss 
increases three times with each decade over 40, the 
demand for eye services will increase exponentially 
as the world population grows older
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